Back to Peptides
Cartalax
Bone Health & Cartilage SupportCartalax is a synthetic short peptide bioregulator derived from cartilage tissue. It supports regeneration of the extracellular cartilage matrix, stimulates fibroblast and chondrocyte activity, and may alleviate symptoms of osteoarthritis and other degenerative joint diseases. Commonly used in short injectable cycles with minimal systemic side effects.
Reconstitute
3 mL BAC + 20mg vial
67 mcg/unit
Daily Range
2–6 mg Subcutaneous (SQ)
Daily
Standard Dose
4 mg
Cycle
4–8 weeks
then reassess
Cartilage regenerationCartalaxpeptide bioregulatorjoint repairosteoarthritis
Dosing & Reconstitution Guide
Preclinical use of Cartalax has involved subcutaneous administration at 100–200 μg per day in short-term studies (7–10 days). No human dosing protocols are approved or validated.
Standard / Gradual Approach
20mg VialstandardPhaseDoseVolume
Weeks 1–22,000 mcg (2.0 mg)30 units (0.30 mL)
Weeks 3–43,000 mcg (3.0 mg)45 units (0.45 mL)
Weeks 5–84,000 mcg (4.0 mg)60 units (0.60 mL)
Weeks 9–125,000 mcg (5.0 mg)75 units (0.75 mL)
Protocol Summary
Subcutaneous (SQ): Daily · Dose range 2–6 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
SubQ
Inject 200 mcg daily for 10–20 days. Repeat every 3–6 months for chronic joint health maintenance. Split into 2–3 smaller daily doses if needed.
🧪 Quick Start
Vial Size
20 mg
BAC Water
3 mL
Concentration
6.67 mcg/unit
Starting Dose
2,000 mcg (2.0 mg) (30 units (0.30 mL))
Maintenance Dose
5,000 mcg (5.0 mg) (75 units (0.75 mL))
Potential Benefits & Use Cases
Cartalax is a research-use-only compound. It is not approved for human or veterinary use. The information provided is for educational and experimental reference only.
Supports fibroblast proliferation and reduces markers of cellular senescence in aged cell cultures (preclinical)
Modulates ECM homeostasis via MMP-9 inhibition and collagen-related gene expression (preclinical)
Stimulates chondrocyte proliferation in both young and old models with geroprotective effects (preclinical)
Upregulates SIRT-1 and SIRT-6 longevity-associated sirtuins (preclinical)
Reduces pro-apoptotic signals (p53, caspase-3) (preclinical)
Clinical data Strong preclinical Limited data
Mechanism of Action
→Stimulates fibroblast activity, increasing collagen and proteoglycan synthesis
→Promotes chondrocyte proliferation and enhances cartilage matrix regeneration
→Modulates inflammation by regulating cytokine and matrix metalloproteinase expression
Lifestyle & Optimization
timing
Consistent daily dosing.
diet
Adequate protein, vitamin C, and collagen precursors for joint and connective tissue support.
exercise
Low-impact exercise and mobility work.
sleep
Prioritize sleep and stress management.
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Study TitleType
Side Effects & Safety
Common Side Effects
• Transient fatigue, mild flu-like sensation (user-reported)
• Mild digestive upset, rare (user-reported)
🧮 Dose Calculator
Concentration
66.7
mcg/unit
Draw Volume
7
units (0.070 mL)
For a 500 mcg dose, draw 7 units on a U-100 insulin syringe
🧬
Bioavailability & Absorption
SubQ Injection
Good bioavailability with targeted impact on cartilage and periarticular tissues
Oral Administration
Poor bioavailability; not recommended unless specially formulated
Half-Life
Approximately 24 hours
Degradation
Rapid enzymatic degradation unless administered subcutaneously
Tissue Specificity
High specificity for cartilage, connective tissue, and synovial environments
⚗️
Peptide Details
Molecular Weight
Formula
Not fully disclosed (synthetic peptide complex)
Sequence
Short peptide bioregulator of cartilage tissue
⚖️
Legal Status & Regulatory
RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved
Storage Instructions
Lyophilized (Powder)
store at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long‑term; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles